A multicenter phase III randomized study with second line chemotherapy plus or minus bevacizumab in patients with platinum sensitive epithelial ovarian cancer recurrence after a bevacizumab/chemotherapy first line
Trial Number
NCT01802749 (ClinicalTrials.gov Identifier)Contact Person
Status
Completed
Disease Site
Ovarian
Lead Cooperative Group
Participating Groups
GINECO
MaNGO
SAKK
BGOG